Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 283 entries
Sorted by: Best Match Show Resources per page
Mycobacterium avium Complex Osteomyelitis in Persons With Human Immunodeficiency Virus: Case Series and Literature Review.

Open forum infectious diseases

Wood BR, Buitrago MO, Patel S, Hachey DH, Haneuse S, Harrington RD.
PMID: 26180837
Open Forum Infect Dis. 2015 Jun 15;2(3):ofv090. doi: 10.1093/ofid/ofv090. eCollection 2015 Sep.

In persons with advanced immunosuppression, Mycobacterium avium complex (MAC) typically causes disseminated disease with systemic symptoms. We report 2 cases in which MAC caused localized osteomyelitis in human immunodeficiency virus (HIV)-infected individuals on antiretroviral therapy with rising CD4 counts....

Cite
Wood BR, Buitrago MO, Patel S, et al. Mycobacterium avium Complex Osteomyelitis in Persons With Human Immunodeficiency Virus: Case Series and Literature Review. Open Forum Infect Dis. 2015;2(3):ofv090doi: 10.1093/ofid/ofv090.
Wood, B. R., Buitrago, M. O., Patel, S., Hachey, D. H., Haneuse, S., & Harrington, R. D. (2015). Mycobacterium avium Complex Osteomyelitis in Persons With Human Immunodeficiency Virus: Case Series and Literature Review. Open forum infectious diseases, 2(3), ofv090. https://doi.org/10.1093/ofid/ofv090
Wood, Brian R, et al. "Mycobacterium avium Complex Osteomyelitis in Persons With Human Immunodeficiency Virus: Case Series and Literature Review." Open forum infectious diseases vol. 2,3 (2015): ofv090. doi: https://doi.org/10.1093/ofid/ofv090
Wood BR, Buitrago MO, Patel S, Hachey DH, Haneuse S, Harrington RD. Mycobacterium avium Complex Osteomyelitis in Persons With Human Immunodeficiency Virus: Case Series and Literature Review. Open Forum Infect Dis. 2015 Jun 15;2(3):ofv090. doi: 10.1093/ofid/ofv090. eCollection 2015 Sep. PMID: 26180837; PMCID: PMC4499669.
Copy Download .nbib Format: NLM
Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma.

Case reports in neurological medicine

Newey CR, George P, Nattanmai P, Ahrens C, Hantus S, Sarwal A.
PMID: 28182114
Case Rep Neurol Med. 2017;2017:9131579. doi: 10.1155/2017/9131579. Epub 2017 Jan 15.

No abstract available.

Cite
Newey CR, George P, Nattanmai P, et al. Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma. Case Rep Neurol Med. 2017;2017:9131579doi: 10.1155/2017/9131579.
Newey, C. R., George, P., Nattanmai, P., Ahrens, C., Hantus, S., & Sarwal, A. (2017). Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma. Case reports in neurological medicine, 20179131579. https://doi.org/10.1155/2017/9131579
Newey, Christopher R, et al. "Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma." Case reports in neurological medicine vol. 2017 (2017): 9131579. doi: https://doi.org/10.1155/2017/9131579
Newey CR, George P, Nattanmai P, Ahrens C, Hantus S, Sarwal A. Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma. Case Rep Neurol Med. 2017;2017:9131579. doi: 10.1155/2017/9131579. Epub 2017 Jan 15. PMID: 28182114; PMCID: PMC5274686.
Copy Download .nbib Format: NLM
A Semi-parametric Transformation Frailty Model for Semi-competing Risks Survival Data.

Scandinavian journal of statistics, theory and applications

Jiang F, Haneuse S.
PMID: 28439147
Scand Stat Theory Appl. 2017 Mar;44(1):112-129. doi: 10.1111/sjos.12244. Epub 2016 Aug 31.

In the analysis of semi-competing risks data interest lies in estimation and inference with respect to a so-called non-terminal event, the observation of which is subject to a terminal event. Multi-state models are commonly used to analyse such data,...

Cite
Jiang F, Haneuse S. A Semi-parametric Transformation Frailty Model for Semi-competing Risks Survival Data. Scand Stat Theory Appl. 2016;44(1):112-129doi: 10.1111/sjos.12244.
Jiang, F., & Haneuse, S. (2017). A Semi-parametric Transformation Frailty Model for Semi-competing Risks Survival Data. Scandinavian journal of statistics, theory and applications, 44(1), 112-129. https://doi.org/10.1111/sjos.12244
Jiang, Fei, and Haneuse, Sebastien. "A Semi-parametric Transformation Frailty Model for Semi-competing Risks Survival Data." Scandinavian journal of statistics, theory and applications vol. 44,1 (2017): 112-129. doi: https://doi.org/10.1111/sjos.12244
Jiang F, Haneuse S. A Semi-parametric Transformation Frailty Model for Semi-competing Risks Survival Data. Scand Stat Theory Appl. 2017 Mar;44(1):112-129. doi: 10.1111/sjos.12244. Epub 2016 Aug 31. PMID: 28439147; PMCID: PMC5400113.
Copy Download .nbib Format: NLM
Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer.

Journal of the American Statistical Association

Lee KH, Dominici F, Schrag D, Haneuse S.
PMID: 28303074
J Am Stat Assoc. 2016;111(515):1075-1095. doi: 10.1080/01621459.2016.1164052. Epub 2016 Oct 18.

Readmission following discharge from an initial hospitalization is a key marker of quality of health care in the United States. For the most part, readmission has been studied among patients with 'acute' health conditions, such as pneumonia and heart...

Cite
Lee KH, Dominici F, Schrag D, et al. Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer. J Am Stat Assoc. 2016;111(515):1075-1095doi: 10.1080/01621459.2016.1164052.
Lee, K. H., Dominici, F., Schrag, D., & Haneuse, S. (2016). Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer. Journal of the American Statistical Association, 111(515), 1075-1095. https://doi.org/10.1080/01621459.2016.1164052
Lee, Kyu Ha, et al. "Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer." Journal of the American Statistical Association vol. 111,515 (2016): 1075-1095. doi: https://doi.org/10.1080/01621459.2016.1164052
Lee KH, Dominici F, Schrag D, Haneuse S. Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer. J Am Stat Assoc. 2016;111(515):1075-1095. doi: 10.1080/01621459.2016.1164052. Epub 2016 Oct 18. PMID: 28303074; PMCID: PMC5347153.
Copy Download .nbib Format: NLM
Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois".

Gastroenterology

Danese S, de la Rue SA, Rutella S.
PMID: 18166365
Gastroenterology. 2008 Jan;134(1):354-5. doi: 10.1053/j.gastro.2007.11.050.

No abstract available.

Cite
Danese S, de la Rue SA, Rutella S. Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois". Gastroenterology. 2008;134(1):354-5doi: 10.1053/j.gastro.2007.11.050.
Danese, S., de la Rue, S. A., & Rutella, S. (2008). Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois". Gastroenterology, 134(1), 354-5. https://doi.org/10.1053/j.gastro.2007.11.050
Danese, Silvio, et al. "Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois"." Gastroenterology vol. 134,1 (2008): 354-5. doi: https://doi.org/10.1053/j.gastro.2007.11.050
Danese S, de la Rue SA, Rutella S. Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois". Gastroenterology. 2008 Jan;134(1):354-5. doi: 10.1053/j.gastro.2007.11.050. PMID: 18166365.
Copy Download .nbib Format: NLM
Infliximab and azathioprine for Crohn's disease: a super-sonic combination?.

Gastroenterology

Peyrin-Biroulet L, Danese S.
PMID: 20659456
Gastroenterology. 2010 Sep;139(3):1059-61. doi: 10.1053/j.gastro.2010.07.035. Epub 2010 Jul 24.

No abstract available.

Cite
Peyrin-Biroulet L, Danese S. Infliximab and azathioprine for Crohn's disease: a super-sonic combination?. Gastroenterology. 2010;139(3):1059-61doi: 10.1053/j.gastro.2010.07.035.
Peyrin-Biroulet, L., & Danese, S. (2010). Infliximab and azathioprine for Crohn's disease: a super-sonic combination?. Gastroenterology, 139(3), 1059-61. https://doi.org/10.1053/j.gastro.2010.07.035
Peyrin-Biroulet, Laurent, and Danese, Silvio. "Infliximab and azathioprine for Crohn's disease: a super-sonic combination?." Gastroenterology vol. 139,3 (2010): 1059-61. doi: https://doi.org/10.1053/j.gastro.2010.07.035
Peyrin-Biroulet L, Danese S. Infliximab and azathioprine for Crohn's disease: a super-sonic combination?. Gastroenterology. 2010 Sep;139(3):1059-61. doi: 10.1053/j.gastro.2010.07.035. Epub 2010 Jul 24. PMID: 20659456.
Copy Download .nbib Format: NLM
Adalimumab for ulcerative colitis: a little is better than none?.

Inflammatory bowel diseases

Danese S.
PMID: 21542069
Inflamm Bowel Dis. 2012 Apr;18(4):793-4. doi: 10.1002/ibd.21773. Epub 2011 May 03.

No abstract available.

Cite
Danese S. Adalimumab for ulcerative colitis: a little is better than none?. Inflamm Bowel Dis. 2011;18(4):793-4doi: 10.1002/ibd.21773.
Danese, S. (2012). Adalimumab for ulcerative colitis: a little is better than none?. Inflammatory bowel diseases, 18(4), 793-4. https://doi.org/10.1002/ibd.21773
Danese, Silvio. "Adalimumab for ulcerative colitis: a little is better than none?." Inflammatory bowel diseases vol. 18,4 (2012): 793-4. doi: https://doi.org/10.1002/ibd.21773
Danese S. Adalimumab for ulcerative colitis: a little is better than none?. Inflamm Bowel Dis. 2012 Apr;18(4):793-4. doi: 10.1002/ibd.21773. Epub 2011 May 03. PMID: 21542069.
Copy Download .nbib Format: NLM
Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases.

Frontiers in immunology

Ungaro F, Rubbino F, Danese S, D'Alessio S.
PMID: 29109724
Front Immunol. 2017 Oct 23;8:1331. doi: 10.3389/fimmu.2017.01331. eCollection 2017.

In the last few decades, the pathogenesis of inflammatory bowel disease (IBD) in genetically predisposed subjects susceptible to specific environmental factors has been attributed to disturbance of both the immune and non-immune system and/or to the imbalanced interactions with...

Cite
Ungaro F, Rubbino F, Danese S, et al. Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. Front Immunol. 2017;8:1331doi: 10.3389/fimmu.2017.01331.
Ungaro, F., Rubbino, F., Danese, S., & D'Alessio, S. (2017). Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. Frontiers in immunology, 81331. https://doi.org/10.3389/fimmu.2017.01331
Ungaro, Federica, et al. "Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases." Frontiers in immunology vol. 8 (2017): 1331. doi: https://doi.org/10.3389/fimmu.2017.01331
Ungaro F, Rubbino F, Danese S, D'Alessio S. Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. Front Immunol. 2017 Oct 23;8:1331. doi: 10.3389/fimmu.2017.01331. eCollection 2017. PMID: 29109724; PMCID: PMC5660440.
Copy Download .nbib Format: NLM
Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719].

EBioMedicine

Gadaleta RM, Garcia-Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, Fiorino G, Danese S, Ko B, Luo J, Porru E, Roda A, Sabbá C, Moschetta A.
PMID: 32650271
EBioMedicine. 2020 Jul;57:102873. doi: 10.1016/j.ebiom.2020.102873. Epub 2020 Jul 07.

No abstract available.

Cite
Gadaleta RM, Garcia-Irigoyen O, Cariello M, et al. Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719]. EBioMedicine. 2020;57:102873doi: 10.1016/j.ebiom.2020.102873.
Gadaleta, R. M., Garcia-Irigoyen, O., Cariello, M., Scialpi, N., Peres, C., Vetrano, S., Fiorino, G., Danese, S., Ko, B., Luo, J., Porru, E., Roda, A., Sabbá, C., & Moschetta, A. (2020). Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719]. EBioMedicine, 57102873. https://doi.org/10.1016/j.ebiom.2020.102873
Gadaleta, Raffaella Maria, et al. "Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719]." EBioMedicine vol. 57 (2020): 102873. doi: https://doi.org/10.1016/j.ebiom.2020.102873
Gadaleta RM, Garcia-Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, Fiorino G, Danese S, Ko B, Luo J, Porru E, Roda A, Sabbá C, Moschetta A. Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719]. EBioMedicine. 2020 Jul;57:102873. doi: 10.1016/j.ebiom.2020.102873. Epub 2020 Jul 07. PMID: 32650271; PMCID: PMC7348001.
Copy Download .nbib Format: NLM
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus.

Gastroenterology research and practice

Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P.
PMID: 31565051
Gastroenterol Res Pract. 2019 Sep 02;2019:3108025. doi: 10.1155/2019/3108025. eCollection 2019.

BACKGROUND: The lifelong and remitting nature of ulcerative colitis results in considerable disability and a substantial negative impact on quality of life. The major goal of the therapy of ulcerative colitis is considered to be the modification of the...

Cite
Daperno M, Armuzzi A, Danese S, et al. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract. 2019;2019:3108025doi: 10.1155/2019/3108025.
Daperno, M., Armuzzi, A., Danese, S., Fries, W., Liguori, G., Orlando, A., Papi, C., Principi, M., Rizzello, F., Viscido, A., & Gionchetti, P. (2019). Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterology research and practice, 20193108025. https://doi.org/10.1155/2019/3108025
Daperno, Marco, et al. "Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus." Gastroenterology research and practice vol. 2019 (2019): 3108025. doi: https://doi.org/10.1155/2019/3108025
Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract. 2019 Sep 02;2019:3108025. doi: 10.1155/2019/3108025. eCollection 2019. PMID: 31565051; PMCID: PMC6745180.
Copy Download .nbib Format: NLM
Emerging therapies for the treatment of ulcerative colitis.

Expert opinion on emerging drugs

Pugliese N, Roda G, Peyrin-Biroulet L, Danese S.
PMID: 32148112
Expert Opin Emerg Drugs. 2020 Mar 09;1-9. doi: 10.1080/14728214.2020.1737009. Epub 2020 Mar 09.

No abstract available.

Cite
Pugliese N, Roda G, Peyrin-Biroulet L, et al. Emerging therapies for the treatment of ulcerative colitis. Expert Opin Emerg Drugs. 2020;1-9doi: 10.1080/14728214.2020.1737009.
Pugliese, N., Roda, G., Peyrin-Biroulet, L., & Danese, S. (2020). Emerging therapies for the treatment of ulcerative colitis. Expert opinion on emerging drugs, 1-9. https://doi.org/10.1080/14728214.2020.1737009
Pugliese, Nicola, et al. "Emerging therapies for the treatment of ulcerative colitis." Expert opinion on emerging drugs vol. (2020): 1-9. doi: https://doi.org/10.1080/14728214.2020.1737009
Pugliese N, Roda G, Peyrin-Biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opin Emerg Drugs. 2020 Mar 09;1-9. doi: 10.1080/14728214.2020.1737009. Epub 2020 Mar 09. PMID: 32148112.
Copy Download .nbib Format: NLM
Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review.

Journal of Crohn's & colitis

Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L.
PMID: 34850857
J Crohns Colitis. 2021 Nov 30; doi: 10.1093/ecco-jcc/jjab218. Epub 2021 Nov 30.

BACKGROUND: Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease. We performed a systematic review to assess the efficacy of different therapies in the management of patients with ulcerative proctitis.METHODS: We identified randomized controlled...

Cite
Caron B, Sandborn WJ, Panaccione R, et al. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis. 2021;doi: 10.1093/ecco-jcc/jjab218.
Caron, B., Sandborn, W. J., Panaccione, R., Schreiber, S., Hart, A., Solitano, V., Danese, S., & Peyrin-Biroulet, L. (2021). Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. Journal of Crohn's & colitis, . https://doi.org/10.1093/ecco-jcc/jjab218
Caron, Bénédicte, et al. "Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review." Journal of Crohn's & colitis vol. (2021). doi: https://doi.org/10.1093/ecco-jcc/jjab218
Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis. 2021 Nov 30; doi: 10.1093/ecco-jcc/jjab218. Epub 2021 Nov 30. PMID: 34850857.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 283 entries